Get the Stockscreener App
17.69
1.67%
0.29
Kailera Therapeutics Inc stock is traded at $17.69, with a volume of 672.85K.
It is up +1.67% in the last 24 hours and down -17.22% over the past month.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
See More
Previous Close:
$17.40
Open:
$17.47
24h Volume:
672.85K
Relative Volume:
0.88
Market Cap:
$2.29B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.64%
1M Performance:
-17.22%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$16.76
$18.03
1-Week Range:
$16.76
$18.98
52-Week Range:
$16.76
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Name
Kailera Therapeutics Inc
Sector
Industry
Phone
508-440-9475
Address
180 THIRD AVENUE, WALTHAM
Compare KLRA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
17.69 | 2.29B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-12-26 | Initiated | Evercore ISI | Outperform |
| May-12-26 | Initiated | JP Morgan | Overweight |
| May-12-26 | Initiated | Jefferies | Buy |
| May-12-26 | Initiated | Leerink Partners | Outperform |
| May-12-26 | Initiated | TD Cowen | Buy |
| May-12-26 | Initiated | William Blair | Outperform |
View All
Kailera Therapeutics Inc Stock (KLRA) Latest News
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
Patent fight erupts around next generation of multibillion-dollar GLP-1 weight-loss drugs - The Business Journals
Yuting Liu Net Worth (2026) - GuruFocus
Jamie Beth Coleman Net Worth (2026) - GuruFocus
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Net Worth (2026) - GuruFocus
Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021 - BioWorld News
Kailera Therapeutics (KLRA) Stock Price, News & Analysis $KLRA - MarketBeat
Scott M. Wasserman Net Worth (2026) - GuruFocus
Stuart Partners, Llc Net Worth (2026) - GuruFocus
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Short Interest Up 96.0% in June - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week LowWhat's Next? - MarketBeat
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart - MEXC
Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential - Yahoo Finance
Kailera's obesity drug meets main goal of late-stage trials in China - MSN
Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win - Seeking Alpha
5 Best IPO Stocks with Huge Upside Potential - Insider Monkey
Kailera Therapeutics (KLRA) officer receives 175,000 stock options at $23.30 strike - Stock Titan
Kailera Therapeutics (KLRA) officer Kathleen Tregoning files initial Form 3 - Stock Titan
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Kailera weight loss pill trial results: Nausea sinks stock - qz.com
Europe will accelerate its review of RevMed’s drug - STAT
Kailera shares tumble on high nausea rates despite weight-loss drug's success | Business Information & News | FE - Westlaw Today
Kailera Therapeutics (KLRA) Company presentation Summary - Quartr
Kailera Therapeutics (KLRA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Kailera Therapeutics (KLRA) Registration filing Summary - Quartr
Kailera falls after late-stage trial data for oral GLP-1 candidate - MSN
Kailera/Hengrui’s Oral GLP-1 Looks Effective, But GI Toxicity Raises Concern - insights.citeline.com
Kailera shares tumble on high nausea rates despite weight-loss drug's success - MSN
Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall - Moomoo
Kailera shares tumble on high nausea rates despite weight-loss drug’s success - Y100 WNCY
The stock price of Kailera Therapeutics, Inc. (KLRA) rose by 1.9% in pre-market trading. - Bitget
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Announces Target Price $57 - Moomoo
Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback - Investor's Business Daily
Kailera reports 11.1% weight loss data - grafa.com
Kailera says obesity pill succeeds in late-stage trial in China - BioPharma Dive
Kailera posts late-stage trial data for oral GLP-1 drug (KLRA) - Seeking Alpha
Kailera Therapeutics Announces Positive Topline Data From Two Hengrui Pharma Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 - marketscreener.com
Kailera’s obesity drug meets main goal of late-stage trials in China - 101 WIXX
Kailera’s weight-loss drug meets main goal of late-stage trials in China - hi99.com
Kailera's weight-loss drug meets main goal of late-stage trials in China - marketscreener.com
Kailera's GLP-1 drug meets main goal of late-stage trials - Yahoo Finance
Kailera Therapeutics Announces Positive Topline Data from - GlobeNewswire
Kailera Therapeutics (KLRA) Stock Looks Overvalued Despite Its 20% Slump - Yahoo Finance
Kailera appoints Kathleen Tregoning as chief corporate affairs officer - The Pharma Letter
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Index - marketscreener.com
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Value Benchmark - marketscreener.com
Kailera Appoints New Chief Corporate Affairs Officer - Intellectia AI
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer - The Manila Times
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Press Release: Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer - Moomoo
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 3000E Value Benchmark - marketscreener.com
Kailera Therapeutics Inc Stock (KLRA) Financials Data
There is no financial data for Kailera Therapeutics Inc (KLRA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Kailera Therapeutics Inc Stock (KLRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
500,000 |
8,000,000 |
10,776,820 |
| BAIN CAPITAL INVESTORS LLC | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
| Koppel Adam | Director |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Bain Capital Life Sciences Inv | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Kaplan Andrew T. | Director |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):